1. DISEASE CHARACTERISTICS 1.1 Name of the disease (synonyms) There are four subclasses of Congenital Generalized Lipodystrophy (CGL), also named Berardinelli-Seip Congenital Lipodystrophy (BSCL):
Type 1 CGL (CGL1).
Type 2 CGL (CGL2). Type 3 CGL (CGL3). Type 4 CGL (CGL4).
It is important to underline that CGL is an expanding group of disorders, whose classification is still underway. In addition to the diseases known as CGL in OMIM, generalized lipodystrophies can be encountered in other Mendelian disorders including severe insulinresistance syndromes, complex progeroid syndromes, as well as autoinflammatory diseases. A de novo variant in the promoter of the FOS gene has also been reported in a generalized lipodystrophy, though this disease has not entered the CGL classification so far. 1 The description of all these rare entities is beyond the scope of this clinical utility gene card, which will focus on the so-called CGL.
1.2 OMIM# of the disease CGL1: #608594. CGL2: #269700. CGL3: #612526. CGL4: #613327.
1.3 Name of the analysed genes or dna/chromosome segments CGL1: AGPAT2. CGL2: BSCL2. CGL3: CAV1. CGL4: PTRF.
OMIM# of the gene(s)
AGPAT2: *603100. BSCL2: *606158. CAV1: *601047. PTRF: *603198.
Mutational spectrum
AGPAT2-CGL1 is an autosomal recessive disorder. Several dozen disease-causing variants have been described. 2 The following molecular defects have been reported: nonsense, missense, splice-site variants, deletions and insertions. 3 Most of them result in frameshift and/or truncated proteins, which are likely to lead to the complete loss of AGPAT2 function. This can be demonstrated in vitro by measurement of AGPAT2 enzymatic activity. 4 BSCL2-CGL2 is an autosomal recessive disorder. Several dozen disease-causing variants have been described. The following molecular defects have been reported: nonsense, missense, splice-site variants, deletions and insertions. 3, 5 Most of them result in frameshift and/or truncated proteins, which are likely to lead to complete loss of BSCL2 function (for more details, see http://databases.lovd.nl/shared/variants/ BSCL2/unique). Notably, disease-causing variants in this gene have also been identified in patients with distal hereditary motor neuropathies or neurodegenerative syndromes. 6 CAV1-disease-causing variants in this gene are very rare. A homozygous nonsense variant was identified in a patient with CGL. 7 In addition, a nonsense variant, two deletions leading to frameshifts and a variant located within the 5′-untranslated region of the gene were reported in the heterozygous state in patients with atypical forms of lipodystrophies, either partial or generalized. [8] [9] [10] Notably, diseasecausing variants in this gene have also been identified in patients described with isolated pulmonary hypertension. 11 PTRF-CGL4 is an autosomal recessive disorder associating generalized lipodystrophy and muscular dystrophy. A bit more than 10 disease-causing variants have been described to date. The following molecular defects have been reported: nonsense, splice-site variants, deletions and insertions. 12 All of them result in frameshift and/or truncated proteins, which are likely to lead to complete loss of PTRF function. Individuals carrying disease-causing variants in the heterozygous state can present minor signs of the disease.
Except for BSCL2, there is no specific database listing molecular defects implicated in CGL.
Analytical methods
Sanger sequencing of PCR products corresponding to the coding regions and conserved splice sites is performed on a routine basis. Next-generation sequencing, including gene-targeted and wholeexome sequencing approaches, is also used. 
Analytical validation
There are several steps in the analytical validation process.
Sequencing of both DNA strands (forward and reverse) is performed. When two heterozygous variants or a homozygous variant are found, testing of the patients' parents is recommended to confirm that the defect is biallelic. More generally, identification of the same variant in the affected proband's relatives provides additional confirmation of the result. When the genetic test is positive, a search of the molecular defects is also recommended on a second independent sample from the patient. Newly discovered variants may be searched for in databases listing benign and pathogenic variants. Pathogenicity of variants can also be tested by in silico prediction methods and functional studies.
Notably, there is to date no external quality assessment dedicated to this specific set of genes proposed by the European Molecular Genetics Quality Network.
1.8 Estimated frequency of the disease (Incidence at birth ('birth prevalence') or population prevalence. If known to be variable between ethnic groups, please report):
Less than 500 patients have been reported worldwide. The population prevalence has been estimated to be about 1 in 10 million. 13 
Diagnostic setting
CGL is characterized by a loss of nearly all the body fat with extreme muscularity. Manifestations appear at birth or during early infancy and are associated with metabolic complications (insulin resistance with acanthosis nigricans and alterations of glucose homeostasis, hypertriglyceridaemia and hepatic steatosis). 
TEST CHARACTERISTICS

Analytical sensitivity (proportion of positive tests if the genotype is present)
Depending on the quality of sequencing methods, the analytical sensitivity is close to 100% for germline variants located in coding regions and flanking intronic sequences. Single-nucleotide polymorphisms (SNPs) within PCR primer-binding sites can result in preferential amplification of a single allele and constitute a rare cause of missed variant, so that careful checking of primer-binding sites for SNPs is essential. Notably, potential deep-intronic variants, variants in promoters, large deletions and duplications would not be detected by Sanger sequencing performed on a routine basis. Next-generation sequencing allows the detection of copy-number variations.
Analytical specificity (proportion of negative tests if the genotype is not present)
100%. The analytical validation described above should avoid falsepositive tests. As CGL are recessive disorders, false-positive results with two unknown sequence variations are not expected.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age, sex or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
When the diagnosis has been properly established based on clinical investigation, family history, imaging and biochemical results, very few negative tests are expected. Molecular testing of AGPAT2 and BSCL2 explain more than 95% of cases, 3 whereas CAV1 and PTRF explain very few of them. When genetic testing is negative in a patient with symptoms evocative of CGL, differential diagnoses can be considered (please see section 3.1).
Clinical specificity (proportion of negative tests if the disease is present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
Close to 100%. A precise quantification is difficult, since molecular testing of CGL genes is not performed on a routine basis in asymptomatic individuals.
Positive clinical predictive value (life time risk to develop the disease if the test is positive)
The positive clinical predictive value is 100%. Incomplete penetrance is extremely rare in autosomal recessive disorders and has not been reported in CGL. As mentioned previously, disease onset is at birth or during early childhood.
Negative clinical predictive value (probability of not developing the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: The negative clinical predictive value is nearly 100%, although a negative test does not exclude the possibility of developing a CGL due to molecular defects in other genes that were not tested.
Index case in that family had not been tested: Genetic testing for a clinically unaffected individual is not indicated in this situation. It would only be undertaken if a variant in a gene responsible for CGL has been identified in the proband.
3. CLINICAL UTILITY 3.1 (Differential) diagnostics: The tested person is clinically affected (To be answered if in 1.9 'A' was marked) Whatever the result of the genetic test, treatment of CGL is mainly directed towards the metabolic alterations that are apparent in each individual. In addition to non-specific therapies, the use of recombinant leptin can be considered. This treatment is approved in the United States and in Japan for CGL, but is only available through compassionate programs in Europe.
Prognosis (please describe)
Genetic testing helps to predict the future course of the disease, as well as the risk of complications (mainly at the metabolic, cardiovascular, bone and gastrointestinal levels). Molecular defects in certain genes are more frequently associated with particular symptoms (eg, among others, AGPAT2 with bone cysts, BSCL2 with mental retardation, CAV1 with hypocalcaemia and PTRF with muscular dystrophy). Knowledge of the genetic cause should lead healthcare providers to customize surveillance for complications, and may inform specific therapeutic approaches. Genetic testing is also crucial for prenatal diagnosis and genetic counseling. Management (please describe) Because CGL are multisystem disorders, follow-up by a multidisciplinary team is important (pediatricians, endocrinologists, cardiologists, nutritionists and surgeons) and regular surveillance and therapeutic management are mandatory. Reconstructive surgery can be proposed in adults. Special education is required for individuals with intellectual disability.
